Demographic Variations and Time to Initiation of Adjunct Treatment following Surgical Resection of Anaplastic Astrocytoma in the United States—A National Cancer Database Analysis

Mayur Sharma,Grant Mckenzie,Jeremy Gaskins,Mehran Yusuf,Shiao Y. Woo,Akshitkumar Mistry,Brian Jeremy Williams

DOI: https://doi.org/10.1227/neu.0000000000002810_128

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Anaplastic Astrocytoma (AA) is a rare primary brain tumor with a significant variation in the type and timing of adjunct treatment (AT) following the surgical resection. METHODS: The National Cancer Database (NCDB) was queried for patients diagnosed with AA from 2004 to 2016. Cox proportional hazards and modeling was used to determine factors influencing survival, including the impact of time to initiation (TTI) of adjuvant therapy. RESULTS: Overall, 5890 patients were identified from the database. The use of combined RT+CT temporally increased from 66.3% (2004-2007) to 79% (2014-2016), p 60 years old), hispanic patients, those with either no or government insurance, those living >20 miles from the cancer facility, those treated at low volume centers ( 8 weeks in 41%, 48%, and 3%, respectively. Compared to patients who received RT + CT, patients were likely to receive RT only as AT either at 4-8 weeks or >8 weeks after the surgical procedure. Patients who received AT within 0-4 weeks had the 3-year OS of 46% compared to 56.7% for patients who received treatment at 4.1-8 weeks. CONCLUSIONS: Across the cohort, nearly 15% of patients received no AT following surgery, with the proportion of patients receiving no AT generally decreasing over time. This decrease corresponds to increased utilization of combined modality AT during the same time span. The highest utilization of combined AT within this cohort was between 4.1-8 weeks following the surgery.

surgery,clinical neurology